Laurus Labs Ltd (BOM:540222) reported strong growth in Q3 2025, with revenue increasing by 18% year-on-year, driven by robust demand in the CDMO business. The company maintained healthy gross margins ...

Revenue: INR1,570 crores, reflecting a 31% year-on-year growth. Gross Margin: 59%, an increase of more than 4% due to better product mix and process improvements. EBITDA: INR389 crores with a margin ...

LAURUS LABS LTD - Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The ...

Shares of Laurus Labs Ltd plunged 15 per cent in Monday's trade amid reports the US State Department issued a 'stop-work' ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

REUTERS - Indian generic drugmaker Laurus Labs Ltd's (LAUL.NS) shares rose as much as 16.36 percent on their market debut on Monday after the company's initial public offering raised $196.6 million.

MUMBAI (Reuters) - Indian generic drug maker Laurus Labs Ltd's (LAUL.NS) initial public offering of shares to raise up to 13.32 billion rupees ($197.58 million) was fully subscribed on the last day of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Indian pharmaceuticals company Laurus Labs Ltd said Friday it is raising equity investment for its biotech unit from global venture ..... US-based private equity firm Warburg Pincus has exited a ...